|
WO2021078925A1
|
|
Methods of treating cancer
|
|
WO2021074372A1
|
|
Inhaler
|
|
WO2021074769A1
|
|
Combination therapy for treating a hematological malignancy
|
|
WO2021074772A1
|
|
Modulators of pnpla3 expression
|
|
WO2021064567A1
|
|
Combination treatment for cancer
|
|
US2021095037A1
|
|
Methods for treating late-onset asthma using benralizumab
|
|
US2021070863A1
|
|
Compositions and methods for treating late stage lung cancer
|
|
WO2021037933A1
|
|
Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer
|
|
WO2021014380A1
|
|
Arginase inhibitors and methods of use thereof
|
|
WO2021013735A1
|
|
Parp1 inhibitors
|
|
WO2021009197A1
|
|
Dose dumping resistant pharmaceutical compositions comrising verinurad
|
|
US2020362027A1
|
|
Methods for treating chronic obstructive pulmonary disease in an enhanced patient population using benralizumab
|
|
WO2020208185A1
|
|
Compositions and methods for improved gene editing
|
|
WO2020201097A1
|
|
Osimertinib for use in the treatment of non-small cell lung cancer
|
|
WO2020200960A1
|
|
Lipocalin mutein for treatment of asthma
|
|
TW202102497A
|
|
Compounds and their use in treating cancer
|
|
WO2020183021A1
|
|
Lanabecestat for weight loss
|
|
WO2020182927A1
|
|
Potassium-binding agents for use in hemodialysis patients
|
|
US2021060043A1
|
|
Methods of treating heart failure with reduced ejection fraction
|
|
WO2020178282A1
|
|
Fused tricyclic compounds useful as anticancer agents
|
